1. Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease
Corey A. Siegel, Chin Hur, Joshua R. Korzenik, G. Scott Gazelle, Bruce E. Sands 
Clinical Gastroenterology and Hepatology 
Volume 4, Issue 8, Pages (August 2006)
DOI: /j.cgh
Copyright © 2006 American Gastroenterological Association Terms and Conditions

2. Figure 1
Schematic of decision analysis model of infliximab for the treatment of Crohn’s disease. Corresponding utilities for the final states in the model are shown at the far right. Dz, disease; AZA SE, azathioprine side effect.
Clinical Gastroenterology and Hepatology 2006 4, DOI: ( /j.cgh )
Copyright © 2006 American Gastroenterological Association Terms and Conditions